|
| Wednesday, April 15, 2015 |
|
|
Nanobiotix: 2014 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its audited consolidated results for the fiscal year ended December 31, 2014. more info >> |
|
| Tuesday, February 24, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Monday, February 23, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Friday, February 20, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Thursday, October 16, 2014 |
|
|
Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205) announced today that it has received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, October 8, 2014 |
|
|
PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205- PEA PME eligible), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer today announces the update of the development plan for NBTXR3. more info >> |
|
| Monday, June 2, 2014 |
|
|
Nanobiotix Presents Successful Phase I Results for Its Lead Nanomedicine Product NBTXR3 at ASCO |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced the successful completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented today at the American Society of Clinical Oncology annual meeting. more info >> |
|
| Tuesday, February 11, 2014 |
|
|
NANOBIOTIX sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3 |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its development plan for the CE marking of NBTXR3, the first product from the NanoXray pipeline. more info >> |
|
| Friday, December 6, 2013 |
|
|
NANOBIOTIX Strengthens its NanoXray Pipeline with the Launch of NBTX-TOPO Development, the First Nanotherapeutic with Embedded Radar |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today, in accordance with its plans, the selection of its new product, NBTX-TOPO, in view of its preclinical development. more info >> |
|
| Monday, September 23, 2013 |
|
|
NANOBIOTIX Strengthens Its Management Team |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the strengthening of its management team to support the company's growth within its business strategy. more info >> |
|
|
|
|
